Clinical Trials Logo

Clinical Trial Summary

Hypothesis:

COPD patients with frequent exacerbations have different pulmonary and systemic immune response than COPD patients without frequent exacerbations and this is related to their microbiome.


Clinical Trial Description

The objective of this project is to determine the pulmonary microbiome and its relationship with the pulmonary and systemic inmune response in COPD patients with frequent (FE) and non frequent exacerbations (NE).

1. The pulmonary immune response.

-The role of mucins, antimicrobial peptides (AMPs), Matrix metalloproteinases (MMPs) and Toll-like receptors (TLRs) as lung defense mechanisms and their possible relationship with the microbiome in COPD and FE patients.

2. The systemic immune response. -The pulmonary and blood inflammatory response and circulating bacterial products as markers of the systemic immune response. ;


Study Design


Related Conditions & MeSH terms

  • Lung Diseases
  • Pulmonary Disease (COPD), Chronic Obstructive
  • Pulmonary Disease, Chronic Obstructive

NCT number NCT03321708
Study type Observational
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact Oriol Sibila, PhD
Phone 932919000
Email osibila@santpau.cat
Status Recruiting
Phase N/A
Start date March 2016
Completion date December 2018